1. Home
  2. PSTV vs SLRX Comparison

PSTV vs SLRX Comparison

Compare PSTV & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • SLRX
  • Stock Information
  • Founded
  • PSTV 1996
  • SLRX N/A
  • Country
  • PSTV United States
  • SLRX United States
  • Employees
  • PSTV N/A
  • SLRX N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • SLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PSTV Health Care
  • SLRX Health Care
  • Exchange
  • PSTV Nasdaq
  • SLRX Nasdaq
  • Market Cap
  • PSTV 12.2M
  • SLRX N/A
  • IPO Year
  • PSTV N/A
  • SLRX N/A
  • Fundamental
  • Price
  • PSTV $0.62
  • SLRX $0.78
  • Analyst Decision
  • PSTV Strong Buy
  • SLRX
  • Analyst Count
  • PSTV 3
  • SLRX 0
  • Target Price
  • PSTV $12.75
  • SLRX N/A
  • AVG Volume (30 Days)
  • PSTV 3.6M
  • SLRX 45.8K
  • Earning Date
  • PSTV 05-19-2025
  • SLRX 05-16-2025
  • Dividend Yield
  • PSTV N/A
  • SLRX N/A
  • EPS Growth
  • PSTV N/A
  • SLRX N/A
  • EPS
  • PSTV N/A
  • SLRX N/A
  • Revenue
  • PSTV $5,824,000.00
  • SLRX N/A
  • Revenue This Year
  • PSTV $13.26
  • SLRX N/A
  • Revenue Next Year
  • PSTV $8.84
  • SLRX N/A
  • P/E Ratio
  • PSTV N/A
  • SLRX N/A
  • Revenue Growth
  • PSTV 18.54
  • SLRX N/A
  • 52 Week Low
  • PSTV $0.24
  • SLRX $0.45
  • 52 Week High
  • PSTV $2.67
  • SLRX $7.20
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 43.68
  • SLRX 52.56
  • Support Level
  • PSTV $0.49
  • SLRX $0.68
  • Resistance Level
  • PSTV $0.90
  • SLRX $0.74
  • Average True Range (ATR)
  • PSTV 0.13
  • SLRX 0.05
  • MACD
  • PSTV -0.01
  • SLRX 0.02
  • Stochastic Oscillator
  • PSTV 17.81
  • SLRX 100.00

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: